Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Exelixis
The Netherlands Cancer Institute
M.D. Anderson Cancer Center
University of Chicago
AstraZeneca
Neonc Technologies, Inc.
Bristol-Myers Squibb
Gazi University
Bristol-Myers Squibb
H. Lee Moffitt Cancer Center and Research Institute
PrECOG, LLC.
National Cancer Institute (NCI)
Washington University School of Medicine
Big Ten Cancer Research Consortium
Big Ten Cancer Research Consortium
Dana-Farber Cancer Institute
University Health Network, Toronto
Bristol-Myers Squibb
Brown University